0 Views

Illumina 

“Market Cap $20.07 B As of May 2014

  • Industry: Biotechs
  • Country: United States
  • CEO: Jay T. Flatley
  • Website: www.illumina.com
  • Employees: 3,000
  • Sales: $1.42 B
  • Headquarters: San Diego, California
Forbes Lists
#1756 Global 2000
  • #549 in Market value
Profile

Illumina, Inc. develops, manufactures and markets life science tools and integrated systems for the analysis of genetic variation and function. It provides a comprehensive line of genetic analysis solutions with products and services that serve a broad range of highly interconnected markets, including sequencing, genotyping, gene expression and molecular diagnostics. The company operates its business through two segments: Life Sciences Business unit and Diagnostics Business unit. The Life Sciences Business unit includes all products and services related to the research market, namely the product lines based on its sequencing, bead-array, vera-code, and real-time PCR technologies. The Diagnostics Business unit focuses on the emerging opportunity in molecular diagnostics. Its customers include leading genomic research centers, academic institutions, government laboratories, and clinical research organizations, as well as pharmaceutical, biotechnology, agrigenomics, and consumer genomics companies. The company’s broad portfolio of systems, consumables, and analysis tools are designed to simplify genetic analysis that addresses a full range of genomic complexity, price points, and throughputs, enabling researchers to select the best solution for their scientific challenge. Illumina was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.”

Illumina History

Illumina was founded in April 1998 by David Walt, Ph.D., Larry Bock, John Stuelpnagel, D.V.M., Anthony Czarnik, Ph.D., and Mark Chee, Ph.D. While working with CW Group, a venture capital firm, Larry and John uncovered what would become Illumina’s BeadArray technology at Tufts University and negotiated an exclusive license to that technology. Illumina completed its initial public offering in July 2000.

Illumina began offering single nucleotide polymorphism (SNP) genotyping services in 2001 and launched its first system, the Illumina BeadLab, in 2002, using GoldenGate Genotyping technology. Illumina currently offers microarray-based products and services for an expanding range of genetic analysis sequencing, including SNP genotyping, gene expression, and protein analysis. Illumina’s technologies are used by a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.

On January 26, 2007, the Company completed the acquisition of Hayward based Solexa, Inc. Solexa was founded in June 1998 by Shankar Balasubramanian, Ph.D. and David Klenerman Ph.D. to develop and commercialize genome sequencing technology invented by the founders in the University of Cambridge. The technology is being used to perform a range of analyses, including whole genome resequencing, gene expression analysis and small ribonucleic acid (RNA) analysis.

In June 2009, Illumina announced the launch of their own Personal Full Genome Sequencing Service at a depth of 30X for $48,000 per genome, and a year later dropped the price to $19,500. This is still too expensive for true commercialization but the price will most likely decrease substantially over the next few years as they realize economies of scale and given the competition with other companies such as Complete Genomics and Knome. As of May 2011, Illumina reduced the price to $4,000.

Illumina acquired Epicentre Biotechnologies, based in Madison, Wisconsin, on January 11, 2011.

On January 25, 2012, Hoffmann-La Roche made an unsolicited bid to buy Illumina for $44.50 per share or about $5.7 billion. Roche tried other tactics, including raising its offer (to $51.00, for about $6.8 billion).

In 2014, the company announced a multi-million dollar product, HiSeqX Ten, that it forecast would provide large-scale whole-genome sequencing for $1,000/genome. The company claimed that forty such machines would be able to sequence more genomes in one year than had been produced by all other sequencers to date.”

*Information from Forbes.com and Wikipedia.org

**Video published on YouTube by “ Illumina Inc

Industry:

Biotechs